Trial Profile
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS in Prostate Cancer Prevention
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs MCS 8 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Health Ever Bio-Tech
- 26 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 11 May 2021 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2023.
- 11 May 2021 Planned End Date changed from 1 Oct 2018 to 1 Dec 2023.